{"success":true,"data":{"pressRelease":{"id":"161894","rtpr_id":"nGNX846TWl-20261006","ticker":"ERNA","exchange":"NASDAQ","all_tickers":["ERNA"],"title":"Ernexa Therapeutics’ ERNA-101 Selected for Flash Talk Presentation at Nature Conferences’ Next-Generation Cancer Therapeutics Meeting Co-Hosted by MD Anderson Cancer Center","author":"Globe Newswire","published_at":"2026-10-06T12:55:00.090Z","article_body":"CAMBRIDGE, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics\n(https://www.globenewswire.com/Tracker?data=z964k5uTiRSstyLNG_QqgQ9qkZ6Asb-aR0W92_xboB0r9-OC8tokwUPlGQlIfqgXIzI7I4NqsehrAnXxrB3pZ2RtjMiQG9R7gaG7_fVWmio=)\n(Nasdaq: ERNA), an industry innovator developing novel cell therapies for the\ntreatment of advanced cancers, today announced that new preclinical data from\nits lead oncology program, ERNA-101, have been selected for a Flash Talk\npresentation at the Next-Generation Cancer Therapeutics meeting\n(https://www.globenewswire.com/Tracker?data=1dCPxc-e21yVGOWL_6Sd_ia1Mmz-nz4D4DVPp_OZNKR9iiXyfeZBX4Md7GoP4cgGurmPeqdtVf0mJANJwVsdBgNlNyfkf4U0dMow1r-gtmzDPvriewD-I_gujpa3g5m3H054rS_j-h-KLYdnenyT7OEgmTGB2LEIkr6EWlM4aFMBabtpV2PBaaavBmgf4L9PgdKx3tCFbNloMoGLnhZtbQ==),\nco-hosted by Nature Conferences and The University of Texas MD Anderson Cancer\nCenter.\n\nThe meeting will take place October 6–8, 2026, on MD Anderson’s campus in\nHouston, Texas. The presentation will highlight ERNA-101’s potential to\naddress a fundamental challenge in ovarian cancer: the immunosuppressive tumor\nmicroenvironment that can limit effective antitumor immune responses. In\npreclinical models of high-grade serous ovarian cancer, ERNA-101 promoted\nimmune cell recruitment and was associated with significant tumor regression\nand enhanced survival. When combined with PD-1 checkpoint blockade, ERNA-101\ndemonstrated enhanced antitumor activity, including complete tumor control and\ndurable responses in the majority of treated animals.\n\n“Selection for presentation at a Nature Conferences meeting co-hosted by MD\nAnderson Cancer Center highlights the strength of our preclinical findings for\nERNA-101, and we look forward to engaging with researchers and oncology\nleaders focused on advancing the next generation of cancer therapies,” said\nSanjeev Luther, President and Chief Executive Officer of Ernexa Therapeutics.\n“Our data demonstrate the potential of our allogeneic, off-the-shelf\napproach to deliver immune-activating cytokines to the tumor microenvironment,\nrecruit key immune cells and enhance the activity of checkpoint blockade. We\nbelieve these findings provide a strong scientific foundation for advancing\nERNA-101 toward the clinic and investigating its potential to address the\nsignificant unmet need in ovarian cancer.”\n\nPresentation Details\n\nTitle: IL7-IL15-iMSCs (ERNA-101): Allogeneic, Off-the-Shelf, Next-Generation\nImmune-Enhancing Cell Therapy of Cancer \nSession: Flash Talk Date: Tuesday, October 6, 2026\nLocation: The University of Texas MD Anderson Cancer Center, Houston, Texas\n\nThe presentation will feature preclinical findings demonstrating ERNA-101’s\nability to recruit T cells and proinflammatory macrophages and promote an\nimmune-active tumor microenvironment in models of high-grade serous ovarian\ncancer. In combination with PD-1 checkpoint blockade, ERNA-101 achieved\ncomplete tumor control and durable responses in the majority of treated\nanimals, with the findings reproduced in a larger cohort. Biodistribution\nstudies also showed localization of ERNA-101 to the tumor microenvironment,\nwith no detectable signal in the peritoneal wash, serum or other organs\nevaluated.\n\nCo-hosted by Nature Conferences and MD Anderson Cancer Center, the\nNext-Generation Cancer Therapeutics meeting will bring together researchers\nfrom academia, biotechnology and the pharmaceutical industry to discuss\nemerging approaches to cancer treatment, including next-generation biologics,\nimmunotherapies, targeted therapies and novel therapeutic platforms. For more\ninformation, please visit the conference website\n(https://www.globenewswire.com/Tracker?data=DYOPRYrt-rv1TvsLOaiL5W75u3zzNCvRoPwanqGtJ1KInUQLNEOIthd9eXuuJnm8HJhnCa2DABwg8YX1qFD5doz2KNZTyWx-PVUi7QctF1ao9hUsbaoE2q7e5wtLYLph8FVRPUvrr8D6Zv2RDUbNET_F8DcfcLBQdHHczixQQQ8=).\n\nFor more information about ERNA-101 and the Company’s development plans,\nvisit www.ernexatx.com\n\nAbout ERNA-101\n\nERNA-101 is Ernexa’s lead oncology program, comprising allogeneic,\noff-the-shelf, induced pluripotent stem cell-derived mesenchymal stromal cells\n(iMSCs) engineered to express IL-7 and IL-15 as a single fusion protein\n(IL-7_IL-15-fusokine). ERNA-101 is designed to deliver an immune-activating\ncytokine payload to the tumor microenvironment, promote antitumor immune\nresponses and potentially enhance the activity of checkpoint blockade. Ernexa\nis advancing ERNA-101 toward clinical development for ovarian cancer.\n\nAbout Ernexa Therapeutics\n\nErnexa Therapeutics (NASDAQ: ERNA) is developing innovative cell therapies for\nthe treatment of advanced cancers. Ernexa’s core technology focuses on\nengineering induced pluripotent stem cells (iPSCs) and transforming them into\ninduced mesenchymal stem cells (iMSCs). Ernexa’s allogeneic synthetic iMSCs\nprovide a scalable, off-the-shelf treatment solution, without needing\npatient-specific cell harvesting.\n\nERNA-101 is the company’s lead cell therapy product, designed to activate\nand regulate the immune system's response to recognize and attack cancer\ncells. The company’s initial focus is to develop ERNA-101 for the treatment\nof ovarian cancer, with the potential to address multiple difficult-to-treat\nsolid tumors.\n\nFor more information, visit www.ernexatx.com.\n\nForward-Looking Statements\n\nThis press release contains forward-looking statements within the meaning of\nSection 27A of the Securities Act of 1933, as amended, and Section 21E of the\nSecurities Exchange Act of 1934, as amended, which are intended to be covered\nby the safe harbor provisions of the Private Securities Litigation Reform Act\nof 1995. Forward-looking statements, in some cases, can be identified by terms\nsuch as \"believe,\" \"may,\" \"will,\" \"estimate,\" \"continue,\" \"anticipate,\"\n\"design,\" \"intend,\" \"expect,\" \"could,\" \"plan,\" \"potential,\" \"predict,\" \"seek,\"\n\"should,\" \"would,\" \"contemplate,\" \"project,\" \"target,\" \"objective,\" or the\nnegative version of these words and similar expressions. Forward looking\nstatements involve known and unknown risks, uncertainties and other factors\nthat may cause Ernexa's actual results, performance or achievements to be\nmaterially different from future results, performance or achievements\nexpressed or implied by the forward-looking statements in this press release,\nincluding, without limitation, risks and uncertainties related to: the\nCompany’s ability to advance ERNA-101 toward and submit an IND application\nto the FDA, including the planned submission in Q4 2026; the timing, design\nand outcomes of the planned first-in-human clinical study of ERNA-101 in\nplatinum-resistant ovarian cancer, including the expected availability of\nclinical data in Q4 2027; the Company’s ability to transition from a\npreclinical-stage company to a clinical-stage company; expectations regarding\nthe versatility and therapeutic potential of the Company’s synthetic iMSC\nplatform, including its ability to be engineered for distinct therapeutic\npurposes across oncology and other disease areas; the Company’s plans to\nbroaden its oncology pipeline by evaluating additional high-need cancer\nindications and advancing next-generation iMSC candidates; the Company’s\nability to identify, develop and advance additional product candidates; the\nCompany’s capital allocation strategy, including the decision to pause\nadditional preclinical development expenditures on ERNA-201 and concentrate\nnear-term resources on ERNA-101 and oncology pipeline expansion; the potential\nfor ERNA-201 to be advanced in the future; the Company’s ability to enter\ninto strategic collaborations or partnerships; the sufficiency of the\nCompany’s capital resources to fund planned operations and achieve\nanticipated milestones; the Company’s ability to obtain and maintain\nregulatory approvals for its product candidates; the Company’s ability to\nattract and retain qualified personnel; the Company’s ability to protect its\nintellectual property and proprietary technology; competition from other\ncompanies developing therapies for the same or similar indications; and\ngeneral market, political and economic conditions. Forward-looking statements\nare based upon Ernexa's current expectations and involve assumptions that may\nnever materialize or may prove to be incorrect. All forward looking statements\nare expressly qualified in their entirety by these cautionary statements. For\na detailed description of Ernexa's risks and uncertainties, you are encouraged\nto review its documents filed with the SEC including its recent filings on\nForm 8-K, Form 10-K and Form 10-Q. You are cautioned not to place undue\nreliance on forward-looking statements, which speak only as of the date on\nwhich they were made. Ernexa does not undertake any obligation to update the\nforward-looking statements contained herein to reflect events that occur or\ncircumstances that exist after the date here of, except as required by\napplicable law.\n\nMedia Contact\nSharon Golubchik\nRAYNZ \nsharon@raynzhealth.com\n\nInvestor Contact\nJenene Thomas \nJTC Team, LLC\n(908) 824-0775\nERNA@jtcir.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/bb12f9ec-b7e7-4d8c-92df-cf27e238c398)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX846TWl-20261006","title":"Ernexa Therapeutics’ ERNA-101 Selected for Flash Talk Presentation at Nature Conferences’ Next-Generation Cancer Therapeutics Meeting Co-Hosted by MD Anderson Cancer Center","author":"Globe Newswire","ticker":"ERNA","created":"2026-10-06T12:55:00.090Z","tickers":["ERNA"],"exchange":"NASDAQ","article_body":"CAMBRIDGE, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics\n(https://www.globenewswire.com/Tracker?data=z964k5uTiRSstyLNG_QqgQ9qkZ6Asb-aR0W92_xboB0r9-OC8tokwUPlGQlIfqgXIzI7I4NqsehrAnXxrB3pZ2RtjMiQG9R7gaG7_fVWmio=)\n(Nasdaq: ERNA), an industry innovator developing novel cell therapies for the\ntreatment of advanced cancers, today announced that new preclinical data from\nits lead oncology program, ERNA-101, have been selected for a Flash Talk\npresentation at the Next-Generation Cancer Therapeutics meeting\n(https://www.globenewswire.com/Tracker?data=1dCPxc-e21yVGOWL_6Sd_ia1Mmz-nz4D4DVPp_OZNKR9iiXyfeZBX4Md7GoP4cgGurmPeqdtVf0mJANJwVsdBgNlNyfkf4U0dMow1r-gtmzDPvriewD-I_gujpa3g5m3H054rS_j-h-KLYdnenyT7OEgmTGB2LEIkr6EWlM4aFMBabtpV2PBaaavBmgf4L9PgdKx3tCFbNloMoGLnhZtbQ==),\nco-hosted by Nature Conferences and The University of Texas MD Anderson Cancer\nCenter.\n\nThe meeting will take place October 6–8, 2026, on MD Anderson’s campus in\nHouston, Texas. The presentation will highlight ERNA-101’s potential to\naddress a fundamental challenge in ovarian cancer: the immunosuppressive tumor\nmicroenvironment that can limit effective antitumor immune responses. In\npreclinical models of high-grade serous ovarian cancer, ERNA-101 promoted\nimmune cell recruitment and was associated with significant tumor regression\nand enhanced survival. When combined with PD-1 checkpoint blockade, ERNA-101\ndemonstrated enhanced antitumor activity, including complete tumor control and\ndurable responses in the majority of treated animals.\n\n“Selection for presentation at a Nature Conferences meeting co-hosted by MD\nAnderson Cancer Center highlights the strength of our preclinical findings for\nERNA-101, and we look forward to engaging with researchers and oncology\nleaders focused on advancing the next generation of cancer therapies,” said\nSanjeev Luther, President and Chief Executive Officer of Ernexa Therapeutics.\n“Our data demonstrate the potential of our allogeneic, off-the-shelf\napproach to deliver immune-activating cytokines to the tumor microenvironment,\nrecruit key immune cells and enhance the activity of checkpoint blockade. We\nbelieve these findings provide a strong scientific foundation for advancing\nERNA-101 toward the clinic and investigating its potential to address the\nsignificant unmet need in ovarian cancer.”\n\nPresentation Details\n\nTitle: IL7-IL15-iMSCs (ERNA-101): Allogeneic, Off-the-Shelf, Next-Generation\nImmune-Enhancing Cell Therapy of Cancer \nSession: Flash Talk Date: Tuesday, October 6, 2026\nLocation: The University of Texas MD Anderson Cancer Center, Houston, Texas\n\nThe presentation will feature preclinical findings demonstrating ERNA-101’s\nability to recruit T cells and proinflammatory macrophages and promote an\nimmune-active tumor microenvironment in models of high-grade serous ovarian\ncancer. In combination with PD-1 checkpoint blockade, ERNA-101 achieved\ncomplete tumor control and durable responses in the majority of treated\nanimals, with the findings reproduced in a larger cohort. Biodistribution\nstudies also showed localization of ERNA-101 to the tumor microenvironment,\nwith no detectable signal in the peritoneal wash, serum or other organs\nevaluated.\n\nCo-hosted by Nature Conferences and MD Anderson Cancer Center, the\nNext-Generation Cancer Therapeutics meeting will bring together researchers\nfrom academia, biotechnology and the pharmaceutical industry to discuss\nemerging approaches to cancer treatment, including next-generation biologics,\nimmunotherapies, targeted therapies and novel therapeutic platforms. For more\ninformation, please visit the conference website\n(https://www.globenewswire.com/Tracker?data=DYOPRYrt-rv1TvsLOaiL5W75u3zzNCvRoPwanqGtJ1KInUQLNEOIthd9eXuuJnm8HJhnCa2DABwg8YX1qFD5doz2KNZTyWx-PVUi7QctF1ao9hUsbaoE2q7e5wtLYLph8FVRPUvrr8D6Zv2RDUbNET_F8DcfcLBQdHHczixQQQ8=).\n\nFor more information about ERNA-101 and the Company’s development plans,\nvisit www.ernexatx.com\n\nAbout ERNA-101\n\nERNA-101 is Ernexa’s lead oncology program, comprising allogeneic,\noff-the-shelf, induced pluripotent stem cell-derived mesenchymal stromal cells\n(iMSCs) engineered to express IL-7 and IL-15 as a single fusion protein\n(IL-7_IL-15-fusokine). ERNA-101 is designed to deliver an immune-activating\ncytokine payload to the tumor microenvironment, promote antitumor immune\nresponses and potentially enhance the activity of checkpoint blockade. Ernexa\nis advancing ERNA-101 toward clinical development for ovarian cancer.\n\nAbout Ernexa Therapeutics\n\nErnexa Therapeutics (NASDAQ: ERNA) is developing innovative cell therapies for\nthe treatment of advanced cancers. Ernexa’s core technology focuses on\nengineering induced pluripotent stem cells (iPSCs) and transforming them into\ninduced mesenchymal stem cells (iMSCs). Ernexa’s allogeneic synthetic iMSCs\nprovide a scalable, off-the-shelf treatment solution, without needing\npatient-specific cell harvesting.\n\nERNA-101 is the company’s lead cell therapy product, designed to activate\nand regulate the immune system's response to recognize and attack cancer\ncells. The company’s initial focus is to develop ERNA-101 for the treatment\nof ovarian cancer, with the potential to address multiple difficult-to-treat\nsolid tumors.\n\nFor more information, visit www.ernexatx.com.\n\nForward-Looking Statements\n\nThis press release contains forward-looking statements within the meaning of\nSection 27A of the Securities Act of 1933, as amended, and Section 21E of the\nSecurities Exchange Act of 1934, as amended, which are intended to be covered\nby the safe harbor provisions of the Private Securities Litigation Reform Act\nof 1995. Forward-looking statements, in some cases, can be identified by terms\nsuch as \"believe,\" \"may,\" \"will,\" \"estimate,\" \"continue,\" \"anticipate,\"\n\"design,\" \"intend,\" \"expect,\" \"could,\" \"plan,\" \"potential,\" \"predict,\" \"seek,\"\n\"should,\" \"would,\" \"contemplate,\" \"project,\" \"target,\" \"objective,\" or the\nnegative version of these words and similar expressions. Forward looking\nstatements involve known and unknown risks, uncertainties and other factors\nthat may cause Ernexa's actual results, performance or achievements to be\nmaterially different from future results, performance or achievements\nexpressed or implied by the forward-looking statements in this press release,\nincluding, without limitation, risks and uncertainties related to: the\nCompany’s ability to advance ERNA-101 toward and submit an IND application\nto the FDA, including the planned submission in Q4 2026; the timing, design\nand outcomes of the planned first-in-human clinical study of ERNA-101 in\nplatinum-resistant ovarian cancer, including the expected availability of\nclinical data in Q4 2027; the Company’s ability to transition from a\npreclinical-stage company to a clinical-stage company; expectations regarding\nthe versatility and therapeutic potential of the Company’s synthetic iMSC\nplatform, including its ability to be engineered for distinct therapeutic\npurposes across oncology and other disease areas; the Company’s plans to\nbroaden its oncology pipeline by evaluating additional high-need cancer\nindications and advancing next-generation iMSC candidates; the Company’s\nability to identify, develop and advance additional product candidates; the\nCompany’s capital allocation strategy, including the decision to pause\nadditional preclinical development expenditures on ERNA-201 and concentrate\nnear-term resources on ERNA-101 and oncology pipeline expansion; the potential\nfor ERNA-201 to be advanced in the future; the Company’s ability to enter\ninto strategic collaborations or partnerships; the sufficiency of the\nCompany’s capital resources to fund planned operations and achieve\nanticipated milestones; the Company’s ability to obtain and maintain\nregulatory approvals for its product candidates; the Company’s ability to\nattract and retain qualified personnel; the Company’s ability to protect its\nintellectual property and proprietary technology; competition from other\ncompanies developing therapies for the same or similar indications; and\ngeneral market, political and economic conditions. Forward-looking statements\nare based upon Ernexa's current expectations and involve assumptions that may\nnever materialize or may prove to be incorrect. All forward looking statements\nare expressly qualified in their entirety by these cautionary statements. For\na detailed description of Ernexa's risks and uncertainties, you are encouraged\nto review its documents filed with the SEC including its recent filings on\nForm 8-K, Form 10-K and Form 10-Q. You are cautioned not to place undue\nreliance on forward-looking statements, which speak only as of the date on\nwhich they were made. Ernexa does not undertake any obligation to update the\nforward-looking statements contained herein to reflect events that occur or\ncircumstances that exist after the date here of, except as required by\napplicable law.\n\nMedia Contact\nSharon Golubchik\nRAYNZ \nsharon@raynzhealth.com\n\nInvestor Contact\nJenene Thomas \nJTC Team, LLC\n(908) 824-0775\nERNA@jtcir.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/bb12f9ec-b7e7-4d8c-92df-cf27e238c398)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-06T12:55:00.128655514Z","server_sent_at_ms":1791291300128},"received_at":"2026-10-06T12:55:00.181Z","source_url":null},"analysis":{"id":"150400","press_release_id":"161894","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["still preclinical-stage; IND not yet submitted","preclinical development of ERNA-201 paused, narrowing the pipeline"],"eventType":"clinical_trial","narrative":"Ernexa Therapeutics announced that new preclinical data for its lead oncology program ERNA-101 were selected for a Flash Talk at the Next-Generation Cancer Therapeutics meeting co-hosted by Nature Conferences and MD Anderson Cancer Center, October 6-8, 2026 in Houston.\n\nIn preclinical models of high-grade serous ovarian cancer, ERNA-101 promoted immune cell recruitment, drove significant tumor regression and enhanced survival, and combined with PD-1 blockade achieved complete tumor control and durable responses in the majority of treated animals.\n\nThe company plans to submit an IND to the FDA in Q4 2026 and expects first clinical data from a first-in-human study in platinum-resistant ovarian cancer in Q4 2027; preclinical spending on ERNA-201 has been paused to concentrate resources on ERNA-101.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Preclinical validation of ERNA-101 ahead of planned Q4 2026 IND filing -- visibility event, not a catalyst."},"keyFigures":{"drugName":"ERNA-101","phaseOfTrial":"Preclinical","customDimensions":{"first_clinical_data":"Q4 2027 expected","ind_plan_submission":"Q4 2026 planned"}},"quotedText":"Selection for presentation at a Nature Conferences meeting co-hosted by MD Anderson Cancer Center highlights the strength of our preclinical findings for ERNA-101","namedEntities":{"people":[{"name":"Sanjeev Luther","role":"President and CEO"},{"name":"Sharon Golubchik","role":"Media Contact, RAYNZ"},{"name":"Jenene Thomas","role":"Investor Contact, JTC Team"}],"products":["ERNA-101","ERNA-201","IL-7_IL-15-fusokine"],"companies":[{"name":"Ernexa Therapeutics","ticker":"ERNA","relationship":"filer"},{"name":"The University of Texas MD Anderson Cancer Center","relationship":"conference co-host"},{"name":"Nature Conferences","relationship":"conference co-host"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"Preclinical data for lead asset ERNA-101 selected for a flash talk at a Nature Conferences/MD Anderson co-hosted meeting. Positive visibility for the pipeline but still preclinical, no clinical or regulatory milestone; not market-moving."},"tickerRelevance":{"others":[],"primary":"ERNA"},"globalImportance":18,"audienceRelevance":12,"eventTypeSecondary":["operations_update"],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"preclinical conference presentation","issuerAuthored":true,"clinicalStageTransition":"pre-IND"}},"event_type":"clinical_trial","event_type_secondary":["operations_update"],"sentiment":"bullish","material_impact_score":2,"narrative":"Ernexa Therapeutics announced that new preclinical data for its lead oncology program ERNA-101 were selected for a Flash Talk at the Next-Generation Cancer Therapeutics meeting co-hosted by Nature Conferences and MD Anderson Cancer Center, October 6-8, 2026 in Houston.\n\nIn preclinical models of high-grade serous ovarian cancer, ERNA-101 promoted immune cell recruitment, drove significant tumor regression and enhanced survival, and combined with PD-1 blockade achieved complete tumor control and durable responses in the majority of treated animals.\n\nThe company plans to submit an IND to the FDA in Q4 2026 and expects first clinical data from a first-in-human study in platinum-resistant ovarian cancer in Q4 2027; preclinical spending on ERNA-201 has been paused to concentrate resources on ERNA-101.","key_figures":{"drugName":"ERNA-101","phaseOfTrial":"Preclinical","customDimensions":{"first_clinical_data":"Q4 2027 expected","ind_plan_submission":"Q4 2026 planned"}},"named_entities":{"people":[{"name":"Sanjeev Luther","role":"President and CEO"},{"name":"Sharon Golubchik","role":"Media Contact, RAYNZ"},{"name":"Jenene Thomas","role":"Investor Contact, JTC Team"}],"products":["ERNA-101","ERNA-201","IL-7_IL-15-fusokine"],"companies":[{"name":"Ernexa Therapeutics","ticker":"ERNA","relationship":"filer"},{"name":"The University of Texas MD Anderson Cancer Center","relationship":"conference co-host"},{"name":"Nature Conferences","relationship":"conference co-host"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-06T12:55:06.121Z","global_importance":18,"audience_relevance":12,"importance_components":{"tickerTier":"micro-cap","eventGravity":"preclinical conference presentation","issuerAuthored":true,"clinicalStageTransition":"pre-IND"}},"durationMs":5928,"modelName":"glm-5.3-flashx"}}